Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells $301,910.11 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Eric Hughes sold 9,533 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $301,910.11. Following the completion of the transaction, the insider directly owned 107,711 shares of the company’s stock, valued at approximately $3,411,207.37. The trade was a 8.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $30.46 on Thursday. The firm’s fifty day moving average price is $33.00 and its two-hundred day moving average price is $26.53. The stock has a market cap of $35.02 billion, a PE ratio of 25.38, a PEG ratio of 10.55 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same period in the prior year, the business earned $0.71 earnings per share. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. Jefferies Financial Group boosted their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Barclays upped their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC increased its stake in shares of Teva Pharmaceutical Industries by 28.4% in the fourth quarter. Corient Private Wealth LLC now owns 49,063 shares of the company’s stock valued at $1,531,000 after buying an additional 10,843 shares during the period. Dorsey Wright & Associates acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $1,640,000. Compound Planning Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $323,000. Invesco Ltd. boosted its holdings in Teva Pharmaceutical Industries by 4.8% in the fourth quarter. Invesco Ltd. now owns 2,710,105 shares of the company’s stock valued at $84,582,000 after acquiring an additional 124,304 shares during the last quarter. Finally, Alpine Woods Capital Investors LLC bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $463,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.